Type 1 Diabetes MellitusNCT04558645
Evaluation of Quality of Life in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic
An observational study of Type 1 Diabetes Mellitus and Covid19, run by Gazi University at 1 site in Turkey (Türkiye).
Trial summary
During the COVID-19 pandemic, the time spent at the home of patients has increased because of national quarantine policies and patients' fear of getting sick. For this reason, in this ongoing process, patients have been unable to go to work regularly due to their chronic diseases (being on administrative leave) and… Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Type 1 Diabetes Mellitus, Covid19
- What is being tested?
- Online Survey
- How many people
- 118 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 18 Sep 2020to 26 Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with type 1 diabetes mellitus and healthy controls between 18-65 years
Who may be able to join
- Having been diagnosed with Type 1 Diabetes Mellitus
- Willing to participate in the study
- Participants whose native language is Turkish
Who cannot join
- Unwilling to participate in the study
- Having a cognitive disorder
- Not being literate
- Individuals who do not have sufficient knowledge and functional levels to fill out the online form
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Quality of Life, Physical Activity and Depression in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic
During the COVID-19 pandemic, the time spent at the home of patients has increased because of national quarantine policies and patients' fear of getting sick. For this reason, in this ongoing process, patients have been unable to go to work regularly due to their chronic diseases (being on administrative leave) and their fear of going out. These reasons have prevented being physically active. The aim of the study is to evaluate the physical activity level, quality of life, glucose control, anxiety, depression, fear of hypoglycemia and loneliness perceptions of patients with type 1 diabetes mellitus during the COVID-19 pandemic period and compared with healthy controls.
- Conditions
- Type 1 Diabetes Mellitus, Covid19
- Being tested
- Online Survey
- Medical subject headings
- Diabetes Mellitus, Type 1, COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Online SurveyOther
Online surveys will be applied to all participants
| Study group | Role | What they receive |
|---|---|---|
| Patients with type 1 diabetes mellitus | Patients with Type 1 diabetes mellitus willing to participate in the study Receives: Other: Online Survey | |
| Healthy controls | Healthy controls without chronic disease willing to participate in the study Receives: Other: Online Survey |
What is being measured
The primary outcome is the main question the study is designed to answer.
Physical activity level
Physical activity level using International Physical Activity Questionnaire - Short Form (IPAQ-SF) will be evaluated.
Measured: Five minutes
General Quality of life
Quality of life using Short Form Health Survey (SF-36) will be evaluated.
Measured: Ten minutes
Secondary outcomes (6)
Depression
Depression using Hospital Anxiety and Depression Scale will be evaluated.
Measured: Three minutes
Anxiety
Anxiety using Hospital Anxiety and Depression Scale will be evaluated.
Measured: Three minutes
Self-reported hypoglycemia
It will be questioned how many times patients have had hypoglycemic attacks (<4 mmol/L and common symptoms) in the last 7 days.
Measured: Last seven day
Loneliness
Loneliness using UCLA Loneliness Scale Short Form (ULS-8) will be evaluated.
Measured: Three minutes
Hypoglisemia fear
Hypoglisemia fear using Hypoglisemia Fear Survey (HFS) will be evaluated.
Measured: Five minutes
Dyspnea
Dyspnea during daily life activites using Modified Medical Research Dyspnea Scale will be evaluated.
Measured: Two minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2020
- Study start18 Sep 2020
- Primary completion18 Dec 2020
- Study completion26 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 1 Diabetes MellitusStudies of the same condition, open and under way.
- More trials run by Gazi UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 118 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gazi University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zeliha ÇELİK, Gazi University
- Investigators
- Zeliha ÇELİK, MSc, Study chair, Gazi UniversityMeral BOŞNAK GÜÇLÜ, Prof, Study director, Gazi UniversityFüsun BALOŞ TÖRÜNER, Prof, Principal investigator, Gazi University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04558645
- Sponsor's protocol ID
- 91610558-604.01.02
- Status last verified
- Dec 2020
- First submitted
- 18 Sep 2020
- Last updated
- 29 Dec 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Dec 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Quality of Life, Physical Activity and Depression in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic
- ClinicalTrials.gov ID
- NCT04558645
- Acronym / sponsor ID
- 91610558-604.01.02
- Conditions
- Type 1 Diabetes Mellitus, Covid19
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 118 participants (actual)
- Lead sponsor
- Gazi UniversityUniversity, hospital or other
- Study start
- 18 Sep 2020 (actual)
- Primary completion
- 18 Dec 2020 (actual)
- Study completion
- 26 Dec 2020 (actual)
- First posted
- 22 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
During the COVID-19 pandemic, the time spent at the home of patients has increased because of national quarantine policies and patients' fear of getting sick. For this reason, in this ongoing process, patients have been unable to go to work regularly due to their chronic diseases (being on administrative leave) and their fear of going out. These reasons have prevented being physically active. The aim of the study is to evaluate the physical activity level, quality of life, glucose control, anxiety, depression, fear of hypoglycemia and loneliness perceptions of patients with type 1 diabetes mellitus during the COVID-19 pandemic period and compared with healthy controls.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with type 1 diabetes mellitus | – | Other: Online SurveyPatients with Type 1 diabetes mellitus willing to participate in the study |
| Healthy controls | – | Other: Online SurveyHealthy controls without chronic disease willing to participate in the study |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with type 1 diabetes mellitus and healthy controls between 18-65 years
Key inclusion criteria (3 listed)
- Having been diagnosed with Type 1 Diabetes Mellitus
- Willing to participate in the study
- Participants whose native language is Turkish
Key exclusion criteria (4 listed)
- Unwilling to participate in the study
- Having a cognitive disorder
- Not being literate
- Individuals who do not have sufficient knowledge and functional levels to fill out the online form
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Online SurveyOnline surveys will be applied to all participants | Other | Healthy controls, Patients with type 1 diabetes mellitus |
Primary outcome
Physical activity level
Time frame: Five minutes
Physical activity level using International Physical Activity Questionnaire - Short Form (IPAQ-SF) will be evaluated.
General Quality of life
Time frame: Ten minutes
Quality of life using Short Form Health Survey (SF-36) will be evaluated.
6 secondary outcomes
Depression
Time frame: Three minutes
Anxiety
Time frame: Three minutes
Self-reported hypoglycemia
Time frame: Last seven day
Loneliness
Time frame: Three minutes
Hypoglisemia fear
Time frame: Five minutes
Dyspnea
Time frame: Two minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Dec 2020.
Related trials for Type 1 Diabetes Mellitus
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Zeliha ÇELİK, MSc study chair
Gazi University
Meral BOŞNAK GÜÇLÜ, Prof study director
Gazi University
Füsun BALOŞ TÖRÜNER, Prof principal investigator
Gazi University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 1 Diabetes Mellitus and Covid19, run by Gazi University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Physical activity level (time frame: Five minutes). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Dec 2020.